Colliders
Zero-sum head-to-heads between contradictory hypotheses, resolved by a shared objective criterion. Pick a side; one wins, one loses.
- ⚛ PROCEED-AD or comparable senescence-targeted clinical readout (target 2027): does combined senolytic depletion (e.g. dasatinib + quercetin) outperform sustained SASP-modulation (e.g. JAK inhibition) on cognitive endpoints in MCI/early-AD over a 24-month window? openEliminate (senolytic) 0 vsModulate (senomorphic) 0
- ⚛ smoke test of SPEC-022 PR 22.2 openSide A 1 vsSide B 0
- ⚛ smoke test of SPEC-022 PR 22.2 openSide A 0 vsSide B 0
- ⚛ smoke test of SPEC-022 PR 22.2 openSide A 0 vsSide B 0
- ⚛ Posthumous brain-bank readout 2027-Q3 of spatially-resolved tau/Aβ chronology openTau-first 0 vsAβ-first 0
- ⚛ some test openA 0 vsB 0